Last edition
News about Global Pharma
Terumo Neuro Secures FDA Premarket Approval for Carotid Stent System
Terumo Neuro's Carotid Stent System is indicated for the treatment of carotid artery stenosis in patients at increased risk for adverse events following carotid endarterectomy.
Global Pharma | 16/04/2025 | By Abha | 464
The system is prepared for magnetic tracking and navigation of third-party catheters, which in the future, will further empower clinicians to perform complex procedures with greater precision and control.
Global Pharma | 16/04/2025 | By Abha | 233
First-in-Human Trial of VAS-101 Topical Curcumin Gel for Sickle Cell Disease Begins in Florida
Ten (10) patients with sickle cell disease will be treated with VAS-101 twice per week over 4 weeks for a total of 8 treatments; their blood will be drawn weekly.
Global Pharma | 15/04/2025 | By Manvi | 344
Norgine Acquires Theravia, Expands Rare Disease Portfolio
Norgine has entered into a definitive agreement to acquire Theravia, enhancing its rare disease portfolio with established treatments in rare haematology and hepatology.
Global Pharma | 15/04/2025 | By Manvi | 366
Biocon Biologics Secures Market Entry Date for Yesafili in US
Biocon Biologics has signed a settlement and license agreement with Regeneron, paving the way to launch its interchangeable aflibercept biosimilar, YESAFILI, in the US by the second half of 2026.
Global Pharma | 15/04/2025 | By Manvi | 246
ActiveProtective Launches FDA-Approved Tango Belt to Prevent Hip Injuries in Older Adults
The Tango Belt, having already received Breakthrough Device Designation by the US Food and Drug Administration (FDA), was further granted marketing authorization as a prescription-only device intended as an adjunctive to standard-of-care to reduce the risk of hip fracture or hip dislocation due to falls in older adults at risk of major hip injury due
Global Pharma | 15/04/2025 | By Manvi | 383
Celltrion's YUFLYMA Achieves FDA Interchangeable Status
YUFLYMA is an FDA-approved, high-concentration (100mg/mL) and citrate-free formulation of Humira® biosimilar, approved for multiple inflammatory indications.
Global Pharma | 15/04/2025 | By Abha | 482
SMPA and NCI Collaborate to Expand Potential of Enzomenib in Precision Oncology
Enzomenib is an investigational, oral, small-molecule currently being clinically evaluated by SMPA in Phase 1/2 clinical trials for relapsed or refractory acute leukemia.
Global Pharma | 15/04/2025 | By Abha | 385
CytoSorbents Appoints Thomas Shannon as VP of Marketing for North America
CytoSorbents Corporation announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing approval, Shannon will lead the marketing strategy and execution for DrugSorb™-ATR in the US and Canada.
Global Pharma | 14/04/2025 | By Manvi | 547
J&J MedTech Completes First Clinical Cases with OTTAVA Robotic Surgical System
Johnson & Johnson MedTech announced completion of the first cases in the clinical trial for the OTTAVA™ Robotic Surgical System. The cases mark the first clinical experience with the OTTAVA System.
Global Pharma | 14/04/2025 | By Manvi | 433
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy